Lanean...
Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials
Monoclonal antibodies (mAbs) that block the programmed death 1 (PD-1) or programmed death-ligand 1 (PD-L1) receptors are the most clinically advanced tumor immunotherapies. Given the broad antitumor efficacy and novel mechanism of action, numerous combinatorial approaches incorporating PD-1/PD-L1 bl...
Gorde:
| Argitaratua izan da: | Oncoimmunology |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Taylor & Francis
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5889289/ https://ncbi.nlm.nih.gov/pubmed/29632719 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1408744 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|